Fallopian Tube Cancer Clinical Trials in St Louis, Missouri

9 recruitingSt Louis, Missouri

Showing 19 of 9 trials

Recruiting
Phase 3

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer+4 more
Genelux Corporation186 enrolled31 locationsNCT05281471
Recruiting
Phase 1Phase 2

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Ovarian CancerEndometrial CancerMetastatic Cancer+6 more
Artios Pharma Ltd442 enrolled79 locationsNCT04657068
Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

Ovarian CarcinomaEsophageal CarcinomaGastric Carcinoma+26 more
National Cancer Institute (NCI)1,600 enrolled152 locationsNCT04314401
Recruiting
Phase 3

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer+1 more
Imunon500 enrolled7 locationsNCT06915025
Recruiting
Phase 3

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Stage III Ovarian CancerStage IV Ovarian CancerStage III Fallopian Tube Cancer+3 more
GOG Foundation220 enrolled58 locationsNCT05659381
Recruiting
Phase 2

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Endometrioid Ovarian CancerFallopian Tube CancerEpithelial Ovarian Cancer+1 more
TORL Biotherapeutics, LLC230 enrolled66 locationsNCT06690775
Recruiting
Not Applicable

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Ovarian CancerFallopian Tube Cancer
M.D. Anderson Cancer Center100 enrolled9 locationsNCT05287451
Recruiting
Phase 2

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Ovarian CancerEndometrial CancerFallopian Tube Cancer+1 more
Corcept Therapeutics270 enrolled45 locationsNCT06906341
Recruiting
Phase 1

A Study of ZN-c3 in Patients With Ovarian Cancer

Solid TumorFallopian Tube CancerEpithelial Ovarian Cancer+1 more
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc140 enrolled24 locationsNCT04516447